Loading clinical trials...

Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells | Clinical Trials | Clareo Health

UNKNOWNPHASE1/PHASE2

Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells

Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells Capable of Differentiation in the Endometrial-decidual Direction

NCT05520112•Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

View on ClinicalTrials.gov

Summary

Treatment of Recurrent pregnancy loss using mesenchymal stem cells capable of differentiation in the endometrial-decidual direction.

Detailed Description

Treatment of Recurrent pregnancy (characterized by the presense of thin endometrium) loss using mesenchymal stem cells capable of differentiation in the endometrial-decidual direction.

Eligibility

Age

18 - 49 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•female patients of reproductive age 18-49 years;
•recurrent pregnancy loss without current pregnancy with thin endometrium;
•unsuccessful IVF cycles due to thin endometrium;
•endometrial thickness is ≤6 mm in the first and second phases of the menstrual cycle;
•uterine infertility associated with endometrial hypoplasia;
•the absence of genetic diseases that prevent pregnancy;
•absence of taking hormonal drugs for 3 months prior to enrollment in the study.

Exclusion Criteria

•patients with congenital malformations of the genital organs: agenesis and aplasia of the uterus, bicornuate uterus, unicornuate uterus, congenital fistula between the uterus and the digestive and urinary tracts, other congenital anomalies of the body and cervix. congenital anomaly of the body and cervix, unspecified, other specified developmental anomalies;
•acute inflammatory processes in the uterus;
•acute or chronic infectious and non-infectious diseases in the acute stage, including HIV, hepatitis B and C, syphilis, tuberculosis, chlamydia, myco-, ureaplasmosis, herpes, toxoplasmosis, rubella, cytomegalovirus, gonorrhea, trichomoniasis, etc.;
•autoimmune diseases;
•patients with malignant tumor including a history;
•patients with benign tumors of the uterus and appendages;
•miscarriage not associated with a thin endometrium, including immunological origin;
•hyper- or hypogonadotropic insufficiency of ovarian function, hyperandrogenemia of any origin;
•allergic reactions in the acute stage, established hypersensitivity to any component of the biomedical cell product;
•permanent therapy with cytostatics, hormones;
+1 more criteria

Locations (1)

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Minsk, Belarus

Key Dates

Start Date

November 1, 2022

Primary Completion Date

December 31, 2023

Completion Date

December 31, 2023

Last Updated

August 29, 2022

Enrollment

ESTIMATED participants

Conditions

Recurrent Pregnancy Loss

Interventions

Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction

BIOLOGICAL

Standard treatment according to the clinical protocols

OTHER

Contacts

Anna G Poleshko, Dr

CONTACT

+375295105774 renovacio888@yandex.ru

Tender Loving Care for Recurrent Pregnancy Loss

NCT06182878

Recurrent Pregnancy Loss

View study

NOT_YET_RECRUITINGNA

Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer

NCT07461077

Advanced AgeRecurrent Pregnancy Loss(RPL)+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 29, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells

Inclusion Criteria

Exclusion Criteria

Tender Loving Care for Recurrent Pregnancy Loss

Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer

Sperm DNA Fragmentation in Recurrent Pregnancy Loss

Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies

TNFα and MFG-E8: Novel Biomarkers to Predict Implantation Failure

A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)